Neurodevelopmental Disorder Gene-Edited Cell Lines for Drug Discovery

Neurodevelopmental disorders (NDDs) affect approximately 15% of children globally, according to the World Health Organization (WHO). These conditions, including autism spectrum disorder (ASD), intellectual disability (ID), attention-deficit/hyperactivity disorder (ADHD), and epilepsy, impose significant lifelong burdens on patients and healthcare systems. The National Cancer Institute (NCI) does not track NDDs, but the National Institute of Mental Health (NIMH) reports that ASD alone affects 1 in 36 children in the United States. Clinical impact includes cognitive impairment, social deficits, and increased mortality risk, often due to comorbidities like epilepsy. Early diagnosis and intervention improve outcomes, but many NDDs lack effective therapies.

NDDs are ideal for mechanistic studies due to their strong genetic components and well-characterized subtypes. Over 1,000 genes have been linked to NDDs, with many converging on common pathways such as synaptic function, chromatin remodeling, and mTOR signaling. Public datasets, including the Simons Simplex Collection (SSC) and the Autism Sequencing Consortium (ASC), provide extensive genomic data. Key open questions include the role of somatic mosaicism, gene-environment interactions, and the development of targeted therapies for specific genetic subtypes.

NDDs arise from disruptions in several key pathways:

• • Synaptic signaling: Imbalance in excitatory/inhibitory neurotransmission, often involving glutamate (GRIN2B) and GABA (GABRB3) receptors.
• • Chromatin remodeling: Mutations in genes like CHD8, ARID1B, and MECP2 alter gene expression programs critical for neurodevelopment.
• • mTOR pathway: Hyperactivation of mTOR signaling (e.g., TSC1/TSC2 loss) leads to abnormal cell growth and synaptic dysfunction.
• • Wnt signaling: Disrupted Wnt/β-catenin pathway (e.g., CTNNB1 mutations) affects neuronal migration and differentiation.

Data from ClinVar, NCBI Gene, and published cohort studies.

Key networks implicated in NDDs:

• • mTOR signaling: TSC1/TSC2, PTEN, AKT, RHEB. Hyperactivation leads to abnormal neuronal growth and synaptic density.
• • RAS-MAPK pathway: Mutations in NF1, BRAF, and MAP2K1 cause RASopathies (e.g., Noonan syndrome) with cognitive deficits.
• • Wnt/β-catenin pathway: CTNNB1, CHD8, and DVL3 mutations disrupt neuronal migration and cortical development.
• • Synaptic signaling networks: GRIN2B, SHANK3, NLGN3, and GABRB3 mutations alter glutamate and GABA receptor function.

Organoids offer advantages over 2D cultures by recapitulating cell-cell interactions and brain region-specific architecture.

• • Genetically engineered mouse models (GEMMs): Conditional knockouts of Ndd genes (e.g., Mecp2, Scn1a, Tsc1) recapitulate behavioral phenotypes.
• • Induced models: Chemically induced (e.g., valproic acid) or viral-mediated gene delivery for acute gene manipulation.
• • Patient-derived xenografts (PDX): Rarely used for NDDs; limited to tumor-associated neurodevelopmental conditions.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. For example, TP53 knockout lines are used to study DNA repair in neural progenitors, while KRAS G12D knock-in models help investigate RAS-MAPK signaling in neurodevelopment. Commercially available, sequence-verified models, such as MECP2 knockout SH-SY5Y cells or SCN1A mutant iPSC lines, accelerate research by providing reproducible, validated tools. These models allow researchers to isolate the effect of a single mutation on neuronal function, synaptic activity, and drug response.

Knockout and knock-in lines validate candidate genes from genome-wide association studies (GWAS). For example, CHD8 knockout in iPSC-derived neurons reveals altered expression of ASD-related genes. Similarly, SCN1A knockout models confirm the role of sodium channel dysfunction in epilepsy.

Isogenic pairs (e.g., wild-type vs. TSC2 knockout) enable high-throughput screening for compounds that rescue mTOR hyperactivation. Resistance modeling is less common in NDDs, but gene-edited lines can test drug efficacy in specific genetic backgrounds.

CRISPR synthetic lethality screens identify genes that, when knocked out, selectively kill cells with specific NDD mutations. For example, screening in TSC1-deficient cells may reveal vulnerabilities to mTOR inhibitors or other targeted therapies.